TSE:COM - Cardiome Pharma Stock Price, News, & Analysis

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume19,585 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. It offers BRINAVESS (vernakalant (IV)) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension. It has operations in Canada, the United States, Europe, and internationally. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-604-6776905

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings Date8/13/2019 (Estimated)
OptionableNot Optionable

Receive COM News and Ratings via Email

Sign-up to receive the latest news and ratings for COM and its competitors with MarketBeat's FREE daily newsletter.

Cardiome Pharma (TSE:COM) Frequently Asked Questions

What is Cardiome Pharma's stock symbol?

Cardiome Pharma trades on the Toronto Stock Exchange (TSX) under the ticker symbol "COM."

How were Cardiome Pharma's earnings last quarter?

Cardiome Pharma Co. (TSE:COM) issued its earnings results on Wednesday, May, 8th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.26) by $0.05. The biopharmaceutical company had revenue of $9.64 million for the quarter, compared to the consensus estimate of $10.53 million. View Cardiome Pharma's Earnings History.

When is Cardiome Pharma's next earnings date?

Cardiome Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, August 13th 2019. View Earnings Estimates for Cardiome Pharma.

What is the consensus analysts' recommendation for Cardiome Pharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardiome Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cardiome Pharma.

Has Cardiome Pharma been receiving favorable news coverage?

News stories about COM stock have been trending neutral this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cardiome Pharma earned a coverage optimism score of 0.0 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the stock's share price in the next few days. View News Stories for Cardiome Pharma.

Who are some of Cardiome Pharma's key competitors?

What other stocks do shareholders of Cardiome Pharma own?

Who are Cardiome Pharma's key executives?

Cardiome Pharma's management team includes the folowing people:
  • Dr. William L. Hunter, Pres, CEO & Director (Age 55)
  • Ms. Sheila M. Grant MBA, Chief Operating Officer
  • Mr. David D. McMasters, Gen. Counsel (Age 59)
  • Mr. Hugues Sachot, Chief Commercial Officer
  • Mr. Justin A. Renz, Chief Financial Officer (Age 46)

How do I buy shares of Cardiome Pharma?

Shares of COM and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Cardiome Pharma's official website?

The official website for Cardiome Pharma is http://www.cardiome.com/.

How can I contact Cardiome Pharma?

Cardiome Pharma's mailing address is 1441 Creekside Dr 6th Floor, VANCOUVER, BC V6J 4S7, Canada. The biopharmaceutical company can be reached via phone at +1-604-6776905.


MarketBeat Community Rating for Cardiome Pharma (TSE COM)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  142 (Vote Outperform)
Underperform Votes:  117 (Vote Underperform)
Total Votes:  259
MarketBeat's community ratings are surveys of what our community members think about Cardiome Pharma and other stocks. Vote "Outperform" if you believe COM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe COM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel